Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Scenic Biotech B.V.. (6/25/18). "Press Release: Scenic Appoints Ulrich Grau as Chairman of the Board".

Organisations Organisation Scenic Biotech B.V.
  Organisation 2 Micromet AG
  Today Amgen Research (Munich) GmbH
  Group Amgen (Group)
Products Product small-molecule drug to modulate DNA/RNA
  Product 2 Lantus®
Person Person Grau, Ulrich (Micromet 201106–2012 COO before Lux Biosciences CEO before Enzon 2002–2005 CSO before BASF/Knoll)

Scenic Biotech BV, a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has appointed Ulrich Grau as Chairman to its Board of Directors.

Ulrich Grau serves also as chairman of i-novion and on the Boards of Affimed and Thermosome. He has over 35 years of experience in the biotechnology and pharmaceutical industries including general management, business development, corporate strategy and the development of new products and technologies. Dr. Grau was Chief Operating Officer at Micromet from 2011 to 2012.

Between 2006 and 2010, he was a founder, President and CEO of Lux Biosciences, Inc., a clinical stage ophthalmic company. Previously, he served as CSO at Enzon, and as President of Research and Development at BASF Pharma/Knoll where he directed a global R&D organization whose development pipeline included adalimumab (Humira®).

The majority of his career was at Aventis Pharma, where he last held the position of Senior VP of Global Late Stage Development. The long-acting insulin Lantus® is based on his inventions made during his early years as a scientist with Hoechst AG.

Ulrich received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three years as a post-doctoral fellow at Purdue University in the field of protein crystallography.

Record changed: 2020-06-26


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Scenic Biotech B.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top